Advertisement
Bayer Schering
Subscribe to Bayer Schering

The Lead

Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis

December 9, 2010 3:49 am | News | Comments

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany

Protagen Deepens Cooperation With Bayer Schering Pharma

June 10, 2010 4:26 am | News | Comments

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, and Bayer...

Prometheus and Bayer Schering Pharma to Apply Novel Diagnostic Platform to Oncology Therapeutic Candidates

March 17, 2010 5:07 am | News | Comments

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, has announced the...

FDA Extends Review of Endo's Testosterone Drug Candidate by 3 Months

September 2, 2009 12:52 pm | News | Comments

CHADDS FORD, Pa. (AP) — The FDA has extended a review of a testosterone drug candidate by three...

View Sample

FREE Email Newsletter

Teva: Court Backs Overturn of Yasmin Patent

August 6, 2009 4:45 am | News | Comments

NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Wednesday a U.S. Court backed a ruling that overturned a patent behind Bayer Schering's birth control pill Yasmin. Teva said the U.S. Court of Appeals for the Federal Circuit supported an earlier ruling made by the U.S.

Bayer Schering Pharma To Open Beijing R & D Center

February 12, 2009 4:28 am | News | Comments

FRANKFURT (AP) — German pharmaceutical company Bayer AG said Thursday it will invest euro100 million ($129 million) in a new global research and development center in Beijing over the next five years.

Barr Announces Approval of Generic Yasmin

May 12, 2008 12:25 pm | News | Comments

Barr Pharmaceuticals, Inc. recently announced that its subsidiary, Barr Laboratories, Inc., has

Bayer Outlines New Global R & D Structures; U.S. Pharma Sites and Future Headquarters

November 13, 2006 10:32 am | Pharmaceutical Processing | Product Releases | Comments

Bayer HealthCare has announced a structural realignment of its global pharmaceutical research and development organization. The company also outlined its future U.S. pharma site plan, and said that New Jersey will be home to its U.S. headquarters for pharmaceuticals.

Advertisement
X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading